Why Women Lose More Muscle on GLP-1s — and How to Protect It
GLP-1 weight loss isn't all fat. Up to 40% of the weight lost is lean mass — and women start with less muscle to spare. The data on who's at risk, what actually works to preserve it, and the emerging pharmacological fix.
The debate over whether GLP-1 medications cause problematic muscle loss was a featured session at the ADA 2026 Scientific Sessions. The answer, like most clinical answers, is: it depends on who you are, how much muscle you started with, and what you're doing alongside the medication.
For women — particularly women in perimenopause, menopause, or with PMOS — the muscle conversation carries extra weight. Women have lower baseline skeletal muscle mass, lower anabolic hormone levels, and face an age-related muscle decline that accelerates after 40. Losing 25-40% of weight as lean mass on a GLP-1 medication isn't the same risk profile for a 35-year-old woman with adequate muscle mass as it is for a 55-year-old woman already dealing with hormonal muscle loss.
What the Clinical Trials Actually Show
| Trial | Drug | Total Weight Loss | Lean Mass Loss | Lean % of Total |
|---|---|---|---|---|
| STEP-1 | Semaglutide 2.4 mg | ~15% | ~13% | ~40% |
| SURMOUNT-1 | Tirzepatide 15 mg | ~21% | ~11% | ~25% |
| SEMALEAN | Semaglutide 2.4 mg | ~13% | −3 kg at 7 mo | Stabilized by 12 mo |
The headline that matters: lean mass loss occurs, but it's proportional to overall weight loss — it's not selective muscle wasting. A systematic review of 36 RCTs found that while the proportion of weight lost from lean tissue was a concern, relative lean mass (as a percentage of total body weight) didn't change or slightly improved. The body is losing both fat and muscle, but it's losing more fat proportionally, so the composition ratio actually gets better.
The SEMALEAN study offered the most nuanced picture: lean mass initially declined (−3 kg at 7 months) but stabilized thereafter. Handgrip strength — a functional measure of muscle quality — actually improved by 4.5 kg at 12 months. And the prevalence of sarcopenic obesity dropped from 49% to 33%. Less muscle in absolute terms, but better-functioning muscle and better overall composition.
Why This Hits Women Differently
The same absolute lean mass loss represents a larger relative impact for women because of baseline differences:
- Lower starting muscle mass. Women have approximately 30-40% less skeletal muscle mass than men. A 3 kg lean mass loss represents a larger percentage of a woman's total muscle than a man's.
- Lower anabolic hormones. Testosterone — the primary driver of muscle protein synthesis — is present at roughly 10-20x lower levels in women. This means rebuilding lost muscle is slower and harder.
- Perimenopause compounds the loss. Estrogen supports muscle maintenance indirectly through its effects on growth hormone, inflammation, and satellite cell activation. As estrogen declines during perimenopause, the body's capacity to maintain muscle mass decreases — at exactly the age when many women are most likely to start GLP-1 therapy.
- The SEMALEAN study found greater weight and fat mass loss in women. More weight lost means more absolute lean mass lost, even if the ratio stays proportional.
The Three-Pillar Protection Strategy
1. Resistance Training (Non-Negotiable)
The S-LITE trial demonstrated that supervised resistance and aerobic training can preserve or even increase lean mass during GLP-1 therapy. This isn't optional advice — it's the strongest evidence-based countermeasure available.
The minimum effective dose: 2-3 sessions per week of progressive resistance training targeting all major muscle groups. Progressive means increasing weight or volume over time, not repeating the same routine indefinitely. Bodyweight exercises are a start; loaded exercises (dumbbells, barbells, machines, cables) are more effective for building muscle in a caloric deficit.
For women specifically, resistance training during GLP-1 therapy serves double duty: it protects against drug-induced lean mass loss AND against the age-related sarcopenia that's accelerating independently during perimenopause and menopause.
2. Protein (The Floor Is Higher Than You Think)
Clinical guidance for protein intake during GLP-1 therapy: 1.2–1.6 g/kg/day. For a 75 kg (165 lb) woman, that's 90–120 grams of protein daily. Most women eating under GLP-1-induced appetite suppression fall well short of this without deliberate effort.
Practical strategies when your appetite is blunted:
- Prioritize protein at every meal — eat the protein source first before anything else
- Protein shakes or high-protein snacks when solid food doesn't appeal
- Spread protein across 3-4 eating occasions rather than trying to hit the target in one meal
- Track protein intake for the first month to calibrate your intuition — most people overestimate how much they're eating
3. Don't Undereat on Top of the Drug
GLP-1 medications suppress appetite. Dramatic caloric restriction on top of that creates a severe energy deficit that accelerates lean mass loss. The medication is already reducing your intake — you don't need to add a crash diet on top of it.
Aim for a moderate caloric deficit, not a maximal one. Eating enough total calories (with adequate protein) to support training and recovery is more important than maximizing the speed of weight loss. Fast weight loss with severe undereating is the highest-risk scenario for muscle loss.
The Pharmaceutical Frontier: Bimagrumab
The BELIEVE study, presented at ADA 2025, combined bimagrumab (a myostatin/activin type II receptor inhibitor) with semaglutide. The results were striking: the combination reduced lean mass loss to approximately 7% of total weight lost — compared to 25-40% with semaglutide alone. Fat loss was preserved and may have been enhanced.
Bimagrumab works by blocking myostatin, a protein that inhibits muscle growth. By removing the brake on muscle protein synthesis while the GLP-1 promotes weight loss, the combination shifts the composition of weight lost dramatically toward fat.
This is still in Phase 2. Functional endpoints (strength, physical performance) remain sparse. But the direction of the data suggests that the muscle-loss problem with GLP-1 therapy may have a pharmacological solution within the next few years — not just the lifestyle-based mitigation strategies available today.
The Bottom Line
GLP-1 medications cause lean mass loss alongside fat loss. The proportion — 25-40% of total weight lost — is consistent with other methods of weight loss, not unique to GLP-1 drugs. Functional muscle quality may actually improve despite absolute mass reduction. The body isn't selectively wasting muscle; it's losing both compartments, with fat loss predominating.
But for women — especially women over 40, in perimenopause, or with already-low muscle mass — the absolute lean mass loss represents a larger bite from a smaller reserve. The mitigation is well-supported: resistance training 2-3x weekly, protein at 1.2-1.6 g/kg/day, and avoiding severe caloric restriction on top of the drug's appetite suppression.
The future solution may be pharmacological — bimagrumab or similar myostatin inhibitors combined with GLP-1 therapy. For now, the weight room and the protein counter are your best tools for protecting what you have while losing what you don't need.